image   Board of Directors

Felice A. de Jong, Ph.D., Founder and Chief Executive Officer

Felice has an extensive and distinguished career in metabolomics, and life science. She holds post-graduate degrees in Technology Management from Macquarie University, Sydney, Australia; Nutritional Biochemistry from the University of Connecticut; and a doctorate in Molecular Biology and Biochemistry from the University of Melbourne, Australia.

Dr. de Jong was Technical Manager, Biochemistry at Boehringer Mannheim (Roche), Australia and the founding President of Sigma Aldrich Australia, developing her first company to a successful venture from the ground up. Dr. de Jong returned to Sigma-Aldrich in Boston, USA where she ran Sigma's neurobiology subsidiary, RBI, as its President.

Felice has been an active leader and proponent in the field of metabolomics since its emergence. She developed metabolomics business and marketing strategies during her 6 years as Senior/ Director of Business Development for Metabolon. Her current focus is the automation of methodologies for the measurement of biological response to stress, i.e. disease, environment, drugs, toxins etc.

 

Chris Beecher, Ph.D., Board Member, Founder and Chief Scientific Officer

Chris has more than 25 years of experience in metabolomics, drug discovery and development, and holds 12 patents and 75 publications. His Ph.D. was awarded in Pharmaceutical Sciences (specialty, Natural Products Chemistry and Biochemistry) from the University of Connecticut in 1986. Dr. Beecher served as Director for Drug Development with Ancile Pharmaceuticals and Associate Director for Natural Products Drug Discovery for Bristol-Myers Squibb (BMS). Before joining BMS, Chris was a tenured Associate Professor in the Department of Medicinal Chemistry and Pharmacognosy in the College of Pharmacy at the University of Illinois at Chicago.

Chris is a metabolomic platform development pioneer. In 2001, Dr. Beecher was appointed as the Director of Metabolic Profiling at Paradigm Genetics, Inc. where he was responsible for building the world?s first parallel metabolomics platform. He later became the sole technical founder of Metabolon, Inc. where he continued to build metabolomics platforms and work in discovery. Following the discovery of the metabolite biomarker sarcosine in prostate cancer, Dr. Beecher became a Professor in the Department of Pathology, at the Medical School of the University of Michigan and assumed the position of Director of the UM Metabolomics Facility. Chris is currently Chief Scientific Officer for IROA Technologies where he oversees the continuous development of next generation metabolomics, data generation and data interpretation platforms.

 

Nicolas Barthelemy

Nicolas Barthelemy is a Life Science Executive with over 20 years of operational experience scaling and transforming buinesses.  He last served as Life Technologies' Chief Commercial Officer until the company's recent acquisition by Thermo Fisher. Prior to that role, Nicolas held various executive-level business and operational positions over his nine-year career in the organization, including serving as President of the $850M Cell Systems Division.  During his tenure, Invitrogen/Life Technologies evolved from an $800M reagent company to a $3.9B global industry leader.

Before joining Life Technologies, Nicolas held a number of leadership positions of increasing responsibilities in Biogen Idec's commercial and manufacturing organizations, as the company grew from $200M to over $1.8B in revenue and expanded internationally. Nicolas began his career at Merck, Inc., where he held technical positions in both the pharmaceutical and vaccine divisions.

Nicolas holds a Master's degree in chemical engineering from the University of California at Berkeley, and an engineering degree from the Ecole Superieure de Physique et Chimie Industrielles (Paris, France).  He resides in San Diego, California.

 

Terry Cross, Board Member

Mr. Cross is a founder of Windward Associates and Executive in Residence of Entrepreneurship, Wayne State University School of Business and has been an Angel investor and businessman for over 40 years. He is a past member of the Board of Directors of Great Lakes Angels and a founding member of The Michigan Venture Capital Association. While he has founded many companies and served on many boards over the years, his current board memberships include: RealKidz; PureEntropy as Chairman; MIST Innovations as Chairman; and Monarch Antenna, a Delphi Corp. spinout. Mr. Cross serves as the first Executive in Residence for Entrepreneurship at The School of Business Administration at Wayne State University in Detroit, MI, where he administers the prestigious Adams Entrepreneurial Fellowship and received the 2005 Distinguished Alumni Award. He currently serves as business plan evaluator for the SEIC Michigan 21st, Century Jobs' Fund Pre Seed Fund, the SEIC Michigan 21st, Century Jobs' Fund Accelerator Fund, and The First Step Fund in Detroit, MI.

Mr. Cross was a co-founder of Sonoma Photonics, recently sold to Lockheed-Martin. He was a founding investor in three startups from MIT's tech transfer department and served on MIT's Laboratory for Manufacturing and Productivity. In September of 2007, he was named to the Task Force for A World Financial Center by the Korea Advanced Institute of Science and Technology, one of Korea's most prestigious institutions. He was employed by Kidder, Peabody in various financial services and investment banking activities in Detroit, New York and San Francisco for 28 years.

 

Todd Fink, Board Member

Todd is co-Founder and Managing Partner of O2 Investment Partners. He is also Chief Operating Officer of REI Investment Group, a real estate development firm located in Bloomfield Hills, Michigan that has successfully completed many substantial mixed-use, commercial, residential and industrial developments historically focused in Michigan and the Midwest region.

Todd's primary responsibilities include oversight of operations, finance, treasury and capital allocation functions for the Orley family's investment platforms.  During his career, Todd has led or participated in multiple business acquisitions, mergers and divestitures, joint venture/partnership arrangements, as well as various financings and re-financings. Previously, Todd was a partner in a major Detroit-based law firm, where he specialized in corporate, real estate finance and mergers and acquisitions.

Todd serves on the Board of Directors of O2's portfolio businesses, Silbond Corporation, Greco Aluminum Railings, Ltd, Mercury Manufacturing Company and IROA Technologies, LLC.

Todd is a graduate of the University of Michigan and Wayne State University Law School.